Table 4.

Effects of antisense oligonucleotides on hepatitis B surface antigen in clinical trials

Agent	Carrier	Treatment regimen	Efficacy*
RO7062931	GalNAc	3.0 mg/kg; Q1 week × 5 doses [68]	0.50 log IU/mL HBsAg reduction
		3.0 mg/kg; Q2 weeks × 3 doses [68]	0.39 log IU/mL HBsAg reduction
		3.0 mg/kg; Q4 weeks × 2 doses [68]	0.28 log IU/mL HBsAg reduction
		4.0 mg/kg; Q4 weeks × 2 doses [68]	0.34 log IU/mL HBsAg reduction
GSK3389404	GalNAc	60 mg; Q1 week × 12 doses [93]	0.34 log IU/mL HBsAg reduction
		120 mg; Q1 week × 12 doses [93]	0.75 log IU/mL HBsAg reduction
		120 mg; Q2 weeks × 6 doses [93]	0.44 log IU/mL HBsAg reduction
Bepirovirsen	Unconjugated	150 mg; 2 times per week × 2 doses; then Q1 week × 2 doses [94]	0.50 log IU/mL HBsAg reduction (treatment-naïve patients)
		300 mg; 2 times per week × 2 doses; then Q1 week × 2 doses [94]	1.56 log IU/mL HBsAg reduction (treatment-naïve patients); 1.99 log IU/mL HBsAg reduction (NA treated patients)

GalNAc, N-acetylgalactosamine; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analogue.

^*HBsAg reductions depicted as mean log IU/mL unless otherwise specified.